Teva Pharm announces approval of Cefprozil tablets and Cefprozil for oral suspension USP (TEVA) 44.25 +0.37: -Update- Co announces the FDA has granted approval for the co's ANDAs for Cefprozil Tablets USP, 250 mg and 500 mg and Cefprozil for Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL. Shipment of these products is expected to commence upon expiry of brand exclusivity later this month. The co's Cefprozil Tablets and Cefprozil for Oral Suspension are the AB-rated generic equivalents of Bristol-Myers Squibb's (BMY) broad-spectrum cephalosporin antibiotic Cefzil. Annual sales Cefzil Tablets and Cefzil for Oral Suspension are approx $114 mln and $116 mln, respectively.